NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Price Target & Analyst Ratings

$86.51

-1.87 (-2.12%)

(As of 03:46 PM ET)

Compare

Today's Range: $86.19
▼
$88.24
50-Day Range: $85.71
▼
$94.48
52-Week Range: $80.53
▼
$117.77

Volume: 724,673 shs
Average Volume: 1.29 million shs
Market Capitalization: $16.28 billion

P/E Ratio: 166.37
Dividend Yield: N/A
Price Target: $115.62

BioMarin Pharmaceutical Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 21 Analyst Ratings

Consensus Analyst Price Target

$115.62
33.65% Upside

High Prediction	$185.00
Average Prediction	$115.62
Low Prediction	$78.00

Type	Current 9/21/22 to 9/21/23	1 Month Ago 8/22/22 to 8/22/23	3 Months Ago 6/23/22 to 6/23/23	1 Year Ago 9/21/21 to 9/21/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$115.62	$115.00	$118.65	$112.86
Predicted Upside	33.65% Upside	25.62% Upside	21.56% Upside	26.09% Upside

Get BioMarin Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

BMRN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioMarin Pharmaceutical Stock vs. The Competition

Type	BioMarin Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	2.57	2.65	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	30.82% Upside	1,469.04% Upside	437.61% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/18/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$120.00	+36.12%
9/15/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$140.00	+57.60%
9/14/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$71.00 ➝ $78.00	-11.04%
9/13/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$120.00	+30.25%
9/13/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$100.00	+8.54%
9/13/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00	+19.40%
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
8/1/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$129.00 ➝ $125.00	+44.31%
8/1/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$118.00 ➝ $108.00	+22.82%
7/27/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$95.00	+8.86%
7/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	$185.00	+110.23%
7/5/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$102.00	+18.76%
6/30/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$127.00	+48.99%
6/30/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral	$103.00 ➝ $96.00	+12.62%
6/30/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Reiterates
4/27/2023	SpectralCast Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Reiterates
4/27/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Maintains
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$81.00	-12.28%
2/28/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold	$119.00 ➝ $112.00	+8.49%
2/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$110.00 ➝ $127.00	+23.01%
2/22/2023	Avian Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
2/22/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/3/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$122.00 ➝ $130.00	+15.21%
12/2/2022	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$130.00	+23.15%
11/29/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $120.00	+21.63%
10/24/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight	$140.00 ➝ $112.00	+24.35%

(Data available from 9/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

BMRN Price Target - Frequently Asked Questions

What is BioMarin Pharmaceutical's consensus rating and price target?: According to the issued ratings of 21 analysts in the last year, the consensus rating for BioMarin Pharmaceutical stock is Moderate Buy based on the current 1 sell rating, 7 hold ratings and 13 buy ratings for BMRN. The average twelve-month price prediction for BioMarin Pharmaceutical is $115.62 with a high price target of $185.00 and a low price target of $78.00. Learn more on BMRN's analyst rating history.
Do Wall Street analysts like BioMarin Pharmaceutical more than its competitors?: Analysts like BioMarin Pharmaceutical less than other Medical companies. The consensus rating score for BioMarin Pharmaceutical is 2.57 while the average consensus rating score for medical companies is 2.65. Learn more on how BMRN compares to other companies.
Is BioMarin Pharmaceutical being upgraded by Wall Street analysts?: Over the previous 90 days, BioMarin Pharmaceutical's stock had 1 upgrade by analysts.

Does BioMarin Pharmaceutical's stock price have much upside?: According to analysts, BioMarin Pharmaceutical's stock has a predicted upside of 25.41% based on their 12-month price targets.
What analysts cover BioMarin Pharmaceutical?: BioMarin Pharmaceutical has been rated by 500.com, Bank of America, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Guggenheim, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, UBS Group, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:BMRN) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial